Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
Andrea ChiricozziGiulia CoscarellaLluis L PuigRonald B VenderJensen YeungY José Manuel CarrascosaStefano PiasericoPaolo GisondiCharles LyndePaulo FerreiraPedro Mendes BastosEsteban DaudénLuiz LeiteJoana ValerioElena Del Alcázar-ViladomiuEva VilarrasaMar Llamas VelascoMario Alessandri-BonettiFrancesco MessinaManfredo BruniEugenia Veronica Di BrizziFederica RicceriAlessia NideggerJan HugoAsfandyar MuftiAthina-Ioanna DaponteLaetitia TeixeiraAnna BalatoMarco RomanelliFrancesca PrignanoSpyridon GkalpakiotisCurdin ConradElizabeth LazaridouNatalia RompotiAlexander J StratigosMiguel NogueiraKetty PerisTiago TorresPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Elderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL-23 inhibitors. However, in stratified analyses conducted in elderly patients, IL-23 inhibitors showed higher drug survival rates than IL-17 inhibitors.